John Canan - 28 Sep 2022 Form 4 Insider Report for Acasti Pharma Inc. (GRCE)

Reporting relationship: Director
Issuer ticker: GRCE
Reported as of: 28 Sep 2022
Net transaction value: $0
SEC form: 4
Accepted by SEC: 30 Sep 2022, 16:19:08 UTC
Prior SEC filing: 13 Dec 2021
Next SEC filing: 12 Dec 2022
Source filing: View source filing
Reporting owner signature: /s/ Jason Comerford, attorney-in fact for Mr.Canan

Key filing fact

John Canan filed Form 4 for Acasti Pharma Inc. (GRCE) on 30 Sep 2022.

Key facts

This page summarizes John Canan's Form 4 filing for Acasti Pharma Inc. (GRCE).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 30 Sep 2022, 16:19.

Change

Previous filing in this sequence was filed on 13 Dec 2021.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

ACST transaction Derivative

Stock Options (Right to Buy)

Award

Transaction value: $0
Shares: +45,000
Change %
Price: $0.000000
Shares after: 45,000
Date: 28 Sep 2022
Ownership: Direct
Underlying class: Class A Common Shares
Underlying amount: 45,000
Exercise price: $0.5900
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

Based on conversion of exercise price of C$0.80 into U.S. dollars based on an exchange rate of C$1.00 = US$0.7321 on the date of grant.

Footnote F2

Stock options granted on 09/28/2022 under Acasti Pharma Inc.'s Stock Option Plan and become exercisable evenly and on a quarterly basis over 36 months.